Keyphrases
Resection
100%
Fluorescence Molecular Imaging
75%
Receptor Targets
75%
Epidermal Growth Factor Receptor
75%
Metastasis
75%
Histopathological Examination
75%
Cetuximab
75%
Tumor
75%
Lymph Node Sampling
75%
Oral Cancer
75%
Oncologic
75%
Prognostic Risk Factors
75%
Preoperative Anemia
75%
Pancreatic Ductal Adenocarcinoma
75%
DNA Copy
75%
Gastrointestinal Stromal Tumor
75%
Genome-wide DNA Methylation
75%
Copy number Variation
75%
Oral Cancer Patients
50%
Fluorescent Tracer
50%
Low Risk
30%
Progressive Disease
30%
Blood Transfusion
28%
Oral Tongue Squamous Cell Carcinoma (OTSCC)
24%
Patient Prognosis
24%
Lymph Node Metastasis
24%
Histological Analysis
24%
Surgical Margin
24%
Lymph Node
24%
Clinical Trials
24%
Node-positive
24%
Image-guided
24%
Formalin-fixed
24%
Primary Tumor
24%
Surgery Patients
24%
Surgical Treatment
24%
Fluorescence Imaging
24%
Tissue Processing
24%
Excision
24%
Resection Margin
24%
Postoperative Therapy
24%
Microscopic Evaluation
24%
Nodal Stage
24%
Risk Stratification
22%
Copy number Analysis
22%
Overall Survival
18%
Disease-free Survival
18%
Perioperative Blood Transfusion
18%
Oncological Outcomes
18%
Tumor-associated
15%
Medicine and Dentistry
Neoplasm
100%
Metastatic Carcinoma
93%
Polyadenylated RNA
75%
Molecular Imaging
75%
Epidermal Growth Factor Receptor
75%
Lymph Node
75%
Cetuximab
75%
RNA Sequence
75%
Ribosome RNA
75%
Oral Cancer
75%
Pancreas Adenocarcinoma
75%
Anemia
75%
Surgery
75%
Gastrointestinal Stromal Tumor
75%
DNA Methylation
75%
Ex Vivo
50%
Radioactive Tracer
50%
Surgery
50%
Blood Transfusion
41%
Exon
28%
Polyadenylic Acid
28%
Postoperative Care
24%
Primary Tumor
24%
Lymph Node Metastasis
24%
Surgical Margin
24%
Clinical Trial
24%
Formaldehyde
24%
Mouth Squamous Cell Carcinoma
24%
False Positive Result
24%
Copy Number Variation
24%
Risk Stratification
24%
Progressive Disease
24%
Overall Survival
16%
Disease Free Survival
16%
Breast Cancer
9%
Ganglioglioma
9%
Gene Fusion
9%
Whole Genome Sequencing
9%
Fusion Gene
9%
Intron
9%
Adverse Effect
8%
Awareness
8%
Proportional Hazards Model
8%
Subgroup Analysis
8%
Cohort Analysis
8%
Predictive Factor
6%
Imatinib
6%
Recurrent Disease
6%
Alpha 1 Antitrypsin
6%
Promoter Region
6%